Skip to main content
OpenTrials
Completed

NCT Number: NCT06249451

Staphylococcus Aureus Bacteraemia (SAB)-Support-Study

The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group).

In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Staphylococcus Aureus Bacteremia Bacteremia Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Staphylococcal Infections Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Greifswald University Medicine

Greifswald, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years
  • Inpatient treatment at the University Medicine Greifswald university hospital
  • First diagnosis of SAB in hospital

Exclusion criteria

  • SAB already known before admission
  • Palliative management within 48 hrs after SAB diagnosis
  • Death within 48 hrs after SAB diagnosis
  • Hospital discharge within 48hrs after SAB diagnosis

Treatment and study plan

Checklist-based phone calls

Other

The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.

On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.

The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines.

Primary outcomes

  1. SOP adherence, calculated as a sum score per patient with the following 8 parameters:

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

    • Drawing of follow-up blood cultures 2-3 days after start of adequate antibiotic therapy
    • Early source control (removal of infected material or drainage of an abscess ≤ 72 hrs)
    • Adequate search for SAB focus and metastatic manifestations
    • TEE in patients with clinical indications (within 4 days of SAB diagnosis)
    • Early start of specific therapy after receipt of results via phone call (≤12 hrs)
    • Adequate dosage of antibiotic
    • Sufficient duration of therapy (at least 14 d for uncomplicated bacteremia and 28 d for complicated bacteremia)
    • Combination therapy with Rifampicin or Fosfomycin, when indicated

Secondary outcomes

  1. Time to specific antimicrobial treatment according to guidelines concerning agent and duration

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

  2. Time to negativity of follow up blood cultures

    Time frame: Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)

  3. Time till TEE is performed (when indicated)

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

  4. Length of hospital stay after SAB diagnosis

    Time frame: Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)

  5. In-hospital mortality (all patients)

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

  6. In-hospital mortality (because of SAB complications)

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

  7. Hospital readmission until day 30 after SAB diagnosis (all patients)

    Time frame: Day of SAB diagnosis until day 30 after diagnosis

  8. Hospital readmission until day 30 after SAB diagnosis (because of SAB complications)

    Time frame: Day of SAB diagnosis until day 30 after diagnosis

  9. Hospital readmission until day 90 after SAB diagnosis (all patients)

    Time frame: Day of SAB diagnosis until day 90 after diagnosis

  10. Hospital readmission until day 90 after SAB diagnosis (because of SAB complications)

    Time frame: Day of SAB diagnosis until day 90 after diagnosis

  11. 90-day all-cause mortality

    Time frame: Day of SAB diagnosis until day 90 after diagnosis

  12. 90-day mortality because of SAB complications

    Time frame: Day of SAB diagnosis until day 90 after diagnosis

  13. Relapse of bacteremia until day 90 after diagnosis

    Time frame: Day of SAB diagnosis until day 90 after diagnosis

  14. Quality of discharge summary (documentation and treatment plan), calculated as a sum score

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

  15. Infectious diseases consultation, when indicated (yes/no)

    Time frame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

Sponsors and collaborators

Lead sponsor

University Medicine Greifswald

Other

Registry information

Official study title

SAB-Support-Study: Can Checklist-based Phone Calls Improve the Quality of Staphylococcus Aureus Bacteraemia (SAB) Management

Acronym: SABOT

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Feb 8, 2024
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.